Tiziana Life Sciences Ltd TLSA
Set alert
0.68 USD -0.12 -14.54%
As of Nov 2, 11:18 AM ET
0.6434 Day range 0.8575
0.6434 52-week range 1.95
- YTD
- -54.11%
- 1 year
- -64.39%
- Open
- 0.823
- Prev close
- 0.80
- Mkt cap
- 88.13M
- Vol
- 1.94M
- Avg vol
- 787.75K
- EPS
- -0.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6434
- High
- 0.8575
- Forward P/E
- -13.63
- Beta
- 0.18
- Short ratio
- 0.57
- Inst. own
- 1.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 0.9492
- 200-d avg
- 0.86445
- 1y target
- 0.00
5Y chart
Events in this range
- Jun 13, 2022Rating: ThinkEquity · — → Buy
- Aug 9, 2024Earnings: —; estimate 0; surprise —%
Signals (98)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 20, 2026 | 6 months ago |
| SMA: Bearish | Jan 19, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| RSI: Overbought | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| RSI: Overbought | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 24, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 2, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| RSI: Overbought | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 8, 2024 | 2 years ago |
| SMA: Bullish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| RSI: Overbought | May 27, 2024 | 2 years ago |
| SMA: Bullish | Apr 15, 2024 | 2 years ago |
| SMA: Bullish | Apr 15, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| SMA: Bearish | Dec 25, 2023 | 2 years ago |
| SMA: Bullish | Dec 18, 2023 | 2 years ago |
| MACD: Sell Signal | Oct 23, 2023 | 3 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| SMA: Bullish | Oct 9, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 9, 2023 | 3 years ago |
| SMA: Bullish | Oct 2, 2023 | 3 years ago |
| SMA: Bearish | Sep 11, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 11, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 4, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 5, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | May 29, 2023 | 3 years ago |
| MACD: Buy Signal | May 29, 2023 | 3 years ago |
| MACD: Sell Signal | May 22, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| RSI: Overbought | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 6, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 9, 2023 | 3 years ago |
| MACD: Sell Signal | Nov 21, 2022 | 3 years ago |
| SMA: Bearish | Oct 17, 2022 | 4 years ago |
| SMA: Bullish | Sep 19, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 4, 2022 | 4 years ago |
| SMA: Bearish | May 2, 2022 | 4 years ago |
| SMA: Bullish | Feb 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 70.76M
- Enterprise value
- 78.46M
- Trailing P/E
- 0.00
- Forward P/E
- -13.63
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 37.86
- EPS (TTM)
- -0.13
- Beta
- 0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -199.50K
- Total cash
- 1.13M
- Total debt
- 179.00K
- Return on equity
- -181.23%
- Shares outstanding
- 103.82M
- Short % of float
- 0.32%
- 50-day average
- 0.9492
- 200-day average
- 0.86445
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate 0.00.
Financials — quick view
TLSA Revenue — annual 0
TLSA Net income — annual -18.43M
TLSA EPS — annual -0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2022 | ThinkEquity | init | — | Buy |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- tizianalifesciences.com
News
- Tiziana's experimental MS treatment meets main goals in mid-stage study
- Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints
- Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial
- Tiziana Completes Phase 2a MS Trial, Topline Data Due In October
- Why Is Tiziana Life Sciences Stock Gaining Thursday?
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7
Your note
Sign in to keep a note on TLSA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sanctuary Advisors, LLC | 0.86% | 907,613 | 618.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.21% | 218,681 | 149.03K | Sep 29, 2024 |
| HSBC Holdings PLC | 0.11% | 115,365 | 78.62K | Sep 29, 2024 |
| Morgan Stanley | 0.10% | 109,747 | 74.79K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 104,291 | 71.07K | Sep 29, 2024 |
| Kovitz Investment Group Partners, Llc | 0.08% | 79,365 | 54.09K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index ETF | 0.15% | 162,797 | 110.95K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 55,884 | 38.08K | Oct 30, 2024 |